ECR logo

Ercros, S.A. Stock Price

BME:ECR Community·€229.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

ECR Share Price Performance

€2.51
-1.17 (-31.84%)
€2.51
-1.17 (-31.84%)
Price €2.51

ECR Community Narratives

There are no narratives available yet.

Recent ECR News & Updates

Ercros, S.A. Key Details

€654.7m

Revenue

€471.2m

Cost of Revenue

€183.5m

Gross Profit

€225.8m

Other Expenses

-€42.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 11, 2025
Earnings per share (EPS)
-0.46
Gross Margin
28.03%
Net Profit Margin
-6.46%
Debt/Equity Ratio
69.9%

Ercros, S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Reasonable growth potential and fair value.

3 Risks
2 Rewards

About ECR

Founded
1817
Employees
1357
CEO
Antonio Zabalza Marti
WebsiteView website
www.ercros.es

Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, caustic potash, caustic soda, chlorine chloroisocyanurates, dichloroethane, ercrosbio, hydrochloric acid, hydrogen peroxide, polyvinyl chloride, potassium carbonate, PVC compounds, sodium chlorate, sodium chlorite, sodium hypochlorite, sulfuric acid, and vinyl chloride. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding compunds, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing of particle, as well as resins, paints, and varnishes in the furniture and decoration industry; sockets and switches in the electrical components sector; and health and packaging items in the textile tanning industry. The Pharmacy division engages in the production of raw materials and pharmaceutical intermediate products from antibiotic, anti-hypertensives, and anti-ulcer drugs. This segment’s products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, fosfomycin calcium and sodium, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Spanish Market Performance

  • 7 Days: -0.4%
  • 3 Months: 10.4%
  • 1 Year: 23.8%
  • Year to Date: 27.0%
In the last week, the market has stayed flat, however the Information Technology sector stood out, gaining 3.4%. Meanwhile, the market is actually up 24% over the past year. As for the next few years, earnings are expected to grow by 5.1% per annum. Market details ›